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Calcium-independent phospholipase A2β (iPLA2β) regulates important physiological pro-
cesses including inﬂammation, calcium homeostasis and apoptosis. It is genetically linked to
neurodegenerative disorders including Parkinson’s disease. Despite its known enzymatic
activity, the mechanisms underlying iPLA2β-induced pathologic phenotypes remain poorly
understood. Here, we present a crystal structure of iPLA2β that signiﬁcantly revises existing
mechanistic models. The catalytic domains form a tight dimer. They are surrounded by
ankyrin repeat domains that adopt an outwardly ﬂared orientation, poised to interact with
membrane proteins. The closely integrated active sites are positioned for cooperative acti-
vation and internal transacylation. The structure and additional solution studies suggest that
both catalytic domains can be bound and allosterically inhibited by a single calmodulin. These
features suggest mechanisms of iPLA2β cellular localization and activity regulation, providing
a basis for inhibitor development. Furthermore, the structure provides a framework to
investigate the role of neurodegenerative mutations and the function of iPLA2β in the brain.
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Calcium-independent phospholipase A2β (iPLA2β, alsoknown as PLA2G6A or PNPLA9) hydrolyses membranephospholipids to produce potent lipid second messen-
gers1,2. Due to its emerging role in neurodegeneration and a
strong genetic link to Parkinson’s disease (PD)3–9, the gene
coding for iPLA2β was designated as PARK14. Originally isolated
from myocardial tissue as an activity stimulated during ische-
mia10,11, the enzyme displays several speciﬁc features including
calcium-independent activity, a preference for plasmalogen
phospholipids with arachidonate at the sn-2 position, an inter-
action with ATP12 and inhibition by calmodulin (CaM) in the
presence of Ca2+13. It was also isolated from macrophages, where
it was thought to act as a housekeeping enzyme, maintaining the
homeostasis of the lipid membrane14. Subsequent studies using
the mechanism-based inhibitor bromoenol lactone (BEL)
revealed involvement of the enzyme in (1) agonist-induced ara-
chidonic acid release15; (2) insulin secretion16; (3) vascular con-
striction/relaxation by Ca2+ signaling through store-operated
calcium entry17,18; (4) cellular proliferation and migration19,20;
and (5) autophagy21,22. Alterations in iPLA2β function have
demonstrated its role in multiple human pathologies including
cardiovascular disease1,23,24, cancer25–27, diabetes28,29, muscular
dystrophy30, nonalcoholic steatohepatitis31, and antiviral
responses32. Correspondingly, inhibitors of iPLA2β have been
sought for therapeutic applications. Highly selective ﬂuoroketone
inhibitors have been designed33–35 and successfully applied in
mouse models of diabetes36 and multiple sclerosis37. Recently,
numerous mutations have been discovered in patients with
neurodegenerative disorders such as infantile neuroaxonal dys-
trophy (INAD)38–40 and PD3–9. The protein was also found in
Lewy bodies and its function was connected to idiopathic PD22,41.
The mechanisms of iPLA2β function in diverse signaling cas-
cades and its role in disease remain poorly understood. More than
half of the iPLA2β amino acid sequence is comprised of putative
protein-interaction domains and motifs (Fig. 1a and Supple-
mentary Figure 1). The sequence can be divided into three parts:
the N-terminal domain, the ankyrin repeat (AR) domain (ANK)
and the catalytic domain (CAT)42. The lipid hydrolysis is exe-
cuted by a Ser-Asp catalytic dyad in close spatial proximity to a
glycine-rich motif. The CAT domain is homologous to patatin, a
ubiquitous plant lipase43. The AR is a 33-residue motif consisting
of a helix–turn–helix structure followed by a hairpin-like loop
forming a conserved L-shaped structure. ARs are found in
thousands of proteins and have evolved as a highly speciﬁc
protein recognition structural scaffold44. In different proteins, 4
to 24 ARs can be stacked side-by-side forming elongated linear
structures. Five conserved amino acids form a hydrophobic core
holding the helical repeats together. The remaining amino acids
are variable, but the three-dimensional structure of the AR is
highly conserved.
The cellular localization of iPLA2β is tissue-speciﬁc and
dynamic (review and references are in45). Different variants of
iPLA2β are associated with the plasma membrane, mitochondria,
endoplasmic reticulum, and the nuclear envelope. iPLA2β lacks
transmembrane domains, but is enriched in putative protein-
interaction motifs. Those include several proline-rich loops and
the extended ANK domain with seven or eight ARs capable of
interacting with multiple cognate receptor proteins44,46. However,
relatively little is known about iPLA2β protein-interaction
mechanisms. It binds CaM kinase (CaMKIIβ) in pancreatic islet
β-cells47 and the endoplamic reticulum (ER) chaperone protein
calnexin (Cnx)48. The functional signiﬁcance and mechanisms of
both interactions remains unknown. Pull-down of proteins iso-
lated from β-cells under mild detergent treatment revealed a
number of other proteins from different cellular compartments,













S465 D598 1–9–14 IQ




Fig. 1 Sequence motifs and the structure of iPLA2β. a Domain composition of iPLA2β. ARs are shown in orange with the novel AR1 in dark orange, catalytic
residues are in magenta, poly-Gly region is in green, and putative CaM-binding motifs in blue. Black lines underneath mark INAD and PD mutations. b
Cartoon representation of the iPLA2β monomer color-coded in a rainbow scheme with the N terminus in blue and the C terminus in red. The catalytic dyad
is shown by magenta spheres. The location of the unstructured loop between ANK and CAT domains is indicated by the dashed gray line and of the
disordered membrane-interacting loop by the black dotted line. The position of the proline-rich insert in the long variant is shown by the grey arrow in this
panel and by the red triangle in panel a
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the Arf1 interactome, which regulates cell morphology49.
Understanding the mechanisms of the diverse iPLA2β functions
requires knowledge of its spatial and temporal localization, which
are most likely guided by poorly understood protein–protein
interactions. Structural studies of iPLA2β are currently limited to
identiﬁcation of the putative CaM-binding sites50, molecular
modeling, and mapping of the membrane interaction loop using
hydrogen/deuterium exchange mass spectrometry51,52.
Here, we present the crystal structure of a mammalian iPLA2β,
which revises previous structural models and reveals several
unexpected features critical for regulation of its catalytic activity
and localization in cells. The protein forms a stable dimer
mediated by CAT domains with both active sites in close proxi-
mity, poised to interact cooperatively and to facilitate transacy-
lation and other potential acyl transfer reactions. The structure
suggests an allosteric mechanism of inhibition by CaM, where a
single CaM molecule interacts with two CAT domains, altering
the conformation of the dimerization interface and active sites.
Surprisingly, ANK domains in the crystal structure are oriented
toward the membrane-binding interface and are ideally posi-
tioned to interact with membrane proteins. This ﬁnding could
explain how iPLA2β differentially localizes within a cell in a
tissue-speciﬁc manner, which is a long-standing question in the
ﬁeld. The structural data also suggest an ATP-binding site in the
AR and outline a potential role for ATP in regulating protein
activity. These structural features and structure-based hypotheses
will be instrumental in deciphering mechanisms of iPLA2β
function in different signaling pathways and their associated
diseases. Mapping the location of neurodegenerative mutations
onto the dimeric structure will shed light on their effect on
protein activity and regulation, improving our understanding of
iPLA2β function in the brain.
Results
Structure of iPLA2β. The structure of the short variant of iPLA2β
(SH-iPLA2β, 752 amino acids) was solved by a combination of
selenomethionine single-wavelength anomalous diffraction
(SAD) with molecular replacement (MR) using two different
protein models. Those include patatin43, which has a 32%
sequence identity to the CAT domain, and four ARs of the
ankyrin-R protein53, with a 20% sequence identity to four C-
terminal ARs of iPLA2β (Supplementary Figure 1). Five addi-
tional ARs and several loop regions in CAT were modeled into
the electron density map. The sequence assignment was guided by
position of 51 selenium peaks and the structure was reﬁned using
3.95 Å resolution data (Supplementary Table 1 and Supplemen-
tary Figure 2). Residues 1–80, 95–103, 113–117, 129–145,
405–408, and 652–670 were omitted from the ﬁnal model.
Regions 81–94, 104–112, and 409–416 were modeled as alanines.
The short variant lacks a proline-rich loop in the last AR (Fig. 1)
and sequence numbering in the paper corresponds to sequence of
the SH-iPLA2β. The structure of the monomer is shown in
Fig. 1b.
The core secondary-structure elements of the CAT domain are
similar to that of patatin with root-mean-square deviation (r.m.s.
d.) of 3.1 Å for 186 Cα atoms (Supplementary Figure 3a).
Consequently, the fold of the CAT domain also resembles that of
cytosolic phospholipase A2α (cPLA2α) catalytic domain54, but to
a signiﬁcantly lesser extent. The active site is localized inside the
globular domain as in the patatin structure. However, in iPLA2β,
the catalytic residues are more solvent accessible than in patatin
(Supplementary Figure 3b). In the latter, the active site is
connected to the surface through two narrow channels (Supple-
mentary Figure 3c) and signiﬁcant conformational changes are
required for phospholipid binding. By contrast, in iPLA2β, the
active site cavity is wide open and can accommodate phospho-
lipids with long polyunasturated fatty acid chains.
The periphery and loop regions differ signiﬁcantly from those
in the patatin structure, with two unique extended proline-rich
loops in iPLA2β. A long C-terminal α-helix (α7 in patatin55) is
kinked in the iPLA2β structure and participates in dimerization
(described below).
Conformation of the ANK domain. The electron density map
reveals nine ARs in the structure of SH-iPLA2β, instead of the
previously predicted eight. AR1 is formed by residues 120–147
with a less conserved AR signature sequence motif (Supplemen-
tary Figure 1). The outer helix of AR1 is poorly ordered and was
omitted from the current model. The C-terminal AR9 is formed
by residues 376–402. Gln396, which is substituted by the 54-
residue proline-rich insert in the long variant (L-iPLA2β), is
located in the short loop connecting two helixes of AR9 (gray
arrow in Fig. 1b). The orientation of the entire ANK domain is
completely unexpected (Figs. 1b, 2b). It is attached to the CAT
domain at the side opposite to the membrane-binding surface and
was thought to form an extended structure oriented away from
the membrane to participate in oligomerization56. In the crystal
structure, it wraps around the CAT domain towards the predicted
membrane-interacting surface. This is achieved by the extended
conformation of an 18 amino-acid-long connecting loop, illu-
strated in Supplementary Figure 4a. Part of the linker is unre-
solved due to poor electron density; however, the assignment of
the ANK and CAT domains to the same molecule is unambig-






Fig. 2 Conﬁguration of the iPLA2β dimer in the crystal structure. a The CAT
and ANK domains of a dimer are shown in cyan and light navy, respectively,
in monomer A and in yellow and orange in monomer B. Putative CaM-
binding 1-9-14 motifs in both monomers are shown in dark blue. Catalytic
dyads are shown by magenta spheres. b Same dimer rotated by 90° around
horizontal axis. The schematic drawing of a membrane illustrates the
orientation of the membrane-binding surface of iPLA2β
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03193-0 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:765 | DOI: 10.1038/s41467-018-03193-0 |www.nature.com/naturecommunications 3
form an extensive hydrophobic interface with CAT. AR9 partially
contributes to this interface as well.
ANK interaction with ATP. iPLA2β is the only known phos-
pholipase that interacts with ATP12. The glycine-rich motif was
initially proposed as an ATP-binding site. However, this motif is
highly conserved through patatin-like phospholipases, where it
forms part of the active site. It is also a common element of α/β
hydrolases, where it functions as an oxyanion hole coordinating
charge distribution during catalysis57. To identify the location of
ATP binding in iPLA2β, we soaked protein crystals with 2′MeSe-
ATP and collected 4.6 Å anomalous data. A single anomalous
peak was consistently found near Trp293 of AR6 (Supplementary
Figure 5a). An electron density, adjacent to this residue, was also
found in the Fo-Fc map calculated from the Se-Met crystal
(Supplementary Figure 5b), where ATP was present during pro-
tein concentration to improve solubility. This strongly suggests
that ATP binds near Trp293. The density was less pronounced in
the native crystal, where the nucleotides diffused out of the
capillary used for crystallization (see Methods). Since the low
resolution of the Se-Met and Se-ATP data did not permit
unambiguous modeling of ATP, we did not include it in the ﬁnal
reﬁnement.
Importantly, AR6 (residues 282–308) adopts an unusual
conformation. One of its helices is two amino acids shorter than
a conventional AR helix. There is a kink of the entire ANK
domain at this position, as compared to ankyrin-R. Potential ATP
binding at this location, where an elongated ANK domain
structure is disrupted by the short α-helix of AR6, suggests that
nucleotides can regulate the conformation and thermodynamic
stability of the ANK domain.
To our knowledge, the interaction of ATP with ARs has been
reported only once in the literature. TRPV1 binds ATP within the
positively charged inner concave surface of three ARs58. In
iPLA2β, AR6 and AR7 also possess several basic residues in a
corresponding surface area. However, the position of the
anomalous peak next to Trp293 suggests a potential stacking
interaction. Interestingly, it was shown that both purine
nucleotides, ATP and GTP, have similar effects on iPLA2β
activity12.
CAT-mediated dimerization of iPLA2β. The crystallographic
asymmetric unit is formed by a dimer of iPLA2β. In contrast with
the original hypothesis of ANK-mediated oligomerization56, this
dimer is formed through CAT domains (Figs. 2, 3). The ANK
domains are oriented outwards in opposite directions, forming a
~150-Å-long elongated structure (Fig. 2). Analytical ultra-
centrifugation (AUC) experiments support the existence of an
elongated dimeric structure in solution (Fig. 4a). The experi-
mental molecular weight (MW) was 152 kDa, corresponding to a
dimer with a theoretical MW of 170 kDa. The friction ratio of 1.9
(compared to 1.4 for bovine serum albumin (BSA)) corresponds
to a signiﬁcant deviation from a globular shape. The isolated
ANK domains did not form oligomers in AUC experiments
(Supplementary Figure 6b).
CAT domains interact through an extended, largely hydro-
phobic dimerization interface with a contact area of ~2,800 Å2
















Fig. 3 Extensive interactions of CAT domains and integrated active sites. a Interaction of the CAT domain of molecule B (CAT-B), shown as cyan surface,
with the CAT domain of molecule A (CAT-A), shown as yellow cartoon with highlighted catalytic dyad residues (magenta sticks) and the oxyanion hole
(green). b The proximity of the active site to the dimerization interface is illustrated with surface representation of CAT-B (light cyan) and structural
elements of the CAT-A active site shown as yellow cartoon, along with the Ser-Asp dyad of CAT-A (magenta stick representation), the oxyanion hole
formed by poly-Gly loop (green), and the π-helix (red) which contains the catalytic Asp. The structured fragment of 1-9-14 motif is shown in blue. c The
view from the membrane-binding surface of the active sites of a dimer with secondary-structure elements and the individual residues color-coded as in b
for molecule A and by light cyan for molecule B. A transparent surface of the dimer is shown in grey. C651 residues of the dimer are represented by yellow
and light cyan spheres. These cysteines were previously reported to be acylated in the presence of acyl-CoA and are located on the membrane side of the
protein surface. d Side view of the same structural elements in orientation orthogonal to that in c, illustrating the distance of catalytic dyad residues from
the membrane-interacting surface and the location of Cys651 at this surface as well as near the dimerization interface
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long loop 554–570, and a part of the central β-sheet. Such an
extensive interaction supports a stable dimer. Correspondingly,
iPLA2β dimerizes even at nanomolar concentrations (Supple-
mentary Figure 6a). To probe the dimerization interface, we
substituted Trp695 with Glu (W695E). Trp695 forms extensive
hydrophobic interactions with the opposite monomer, including
a stacking interaction with its counterpart (Supplementary
Figure 4b). The mutant is a monomer in solution (Fig. 4a) and
is inactive (Supplementary Figure 6d). The W695A mutant exists
in equilibrium with both monomeric and dimeric peaks
(Supplementary Figure 6c).
The monomers are related by a twofold axis rotational
symmetry. Two active centers and the predicted membrane-
binding loops51 are oriented in the same direction (Fig. 3d).
Importantly, the active sites are in the immediate vicinity of the
dimerization interface and in close spatial proximity to each other
(Fig. 3). The catalytic Asp598 is at the beginning of a π-helical
loop (599–603) and two leucines of this loop form contacts with
the long α-helix (604–624) of the opposite monomer. This
arrangement suggests a strong allosteric association between the
two active sites and dependence of the catalytic activity on a
dimer conformation.
CaM-binding mechanism. CaM inhibits iPLA2β enzymatic
activity in the presence of calcium. It was proposed to tightly
interact with iPLA2β even at low calcium concentrations59 and to
be displaced by active mechanisms, such as covalent modiﬁcation
of the active site by acyl-CoA60 or by interaction with a calcium
inﬂux factor released from the ER during calcium depletion61.
Two putative CaM-binding peptides containing the canonical IQ
and 1-9-14 motifs were previously isolated by tryptic footprinting
and afﬁnity chromatography using CaM-agarose50. We measured
the Ki of iPLA2β inhibition by CaM using a ﬂuorogenic activity
assay with Pyrene-PC (1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-
glycero-3-phosphocholine) ﬂuorescent phospholipid liposomes
(Supplementary Figure 7a–e). The results revealed a tight
calcium-dependent interaction with CaM with a Ki of 23 ± 1.5 nM
(s.e.m of three replicates) (Fig. 4b) and a Hill coefﬁcient n= 2.2 ±
0.2, indicating potential cooperativity. Next, we measured the
direct interaction of CaM with iPLA2β using ﬂuorescent polar-
ization with ﬂuorescein (FAM)-labeled CaM (Fig. 4c). The dis-
sociation constant of the interaction of CaM with iPLA2β (Kd) of
112 ± 5 nM was higher than the Ki measured with unmodiﬁed
CaM; however, it corresponds to the Ki of FAM-CaM (Supple-
mentary Figure 7g). No cooperativity was observed in the direct
binding experiment.
Remarkably, the interaction of FAM-CaM with the monomeric
W695E mutant was at least an order of magnitude weaker, with a
Kd > 1,400 nM (Fig. 4c), suggesting that iPLA2β dimerization is
crucial for CaM binding. The interaction of CaM with synthetic
isolated FAM-labeled peptides corresponding to 1-9-14 and IQ
motifs was even weaker. Afﬁnity towards the 1-9-14 motif (Kd=
2,500 ± 400 nM) was comparable to that of the monomeric
W695E mutant. Binding of the IQ motif was signiﬁcantly weaker
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Fig. 4 iPLA2β dimerization and mechanism of CaM inhibition. a Sedimentation velocity s(w) distributions of wild-type iPLA2β shown in blue (peak MW:
152 kDa; theoretical MW: 170 kDa), of the W695E mutant in orange (83 kDa), and of W695E in the presence of CaM/Ca2+ in red (138 kDa). Lower MW
can be due to unresolved contribution of minor fraction of monomeric species in the latter case. b Inhibition of iPLA2β enzymatic activity by CaM in the
presence (black) and absence (blue) of Ca2+. c Interaction of FAM-CaM/Ca2+ with iPLA2β as measured by ﬂuorescence anisotropy upon titration by wild-
type iPLA2β (black) and the W695E mutant (red). Error bars represent average ± s.e.m of triplicate experiments, which were performed at least twice
independently. d, e Two orthogonal views of the iPLA2β dimer with monomers color coded in cyan and yellow. CaM in the conformation as reported in the
3SJQ PDB structure is placed next to 1-9-14 motifs (highlighted in blue) to illustrate the possibility of CaM interaction with two 1-9-14 motifs of a dimer
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excess of CaM enabled W695E dimerization in sedimentation
velocity AUC experiments (Fig. 4a). These data strongly support
the model where a single CaM molecule interacts with an iPLA2β
dimer and explains the potential cooperativity in the inhibition
assay. Furthermore, the two 1-9-14 motifs are located on the same
side of the dimer and are ~30 Å apart from each other (Fig. 4d, e).
In the structure of the small conductance potassium channel
complex with CaM (PDBID: 3SIQ)62, a single CaM molecule in
an extended conformation interacts with the channel dimer and
the distance between CaM-binding helixes is also 30 Å.
In Fig. 4d, e, CaM from the 3SIQ complex is placed next to an
iPLA2β dimer to illustrate comparable distances. At the same
time, the conformation of the IQ motif in the tertiary structure
makes it an unlikely target of CaM binding. This motif overlaps
with a β-strand of the conserved structural core of the molecule
and is inaccessible for binding without protein unfolding.
Moreover, mutation of the most conserved hydrophobic Ile to a
charged Asp (I701D) in the IQ motif did not affect iPLA2β
inhibition by CaM (Supplementary Figure 7f). Together, results
from solution studies and the conformation of potential CaM-
binding sites in the iPLA2β dimer suggest that one CaM molecule
interacts with two monomers of the iPLA2β dimer, most likely
through the 1-9-14 motifs.
Discussion
The crystal structure of iPLA2β has revealed several unexpected
features underlying its enzymatic activity and mechanisms of
regulation. Previous computer modeling studies, based on the
patatin structure, proposed an interfacial activation mechanism
whereby interaction with membrane leads to opening of a closed
active site34. In the iPLA2β crystal structure, the active site adopts
an open conformation in the absence of membrane interaction
(Supplementary Figure 3b). Both active sites of the dimer are wide
open and provide sufﬁcient space for phospholipids to access the
catalytic centers. This is in contrast to patatin, where only two
narrow channels connect the catalytic dyad with the solvent-
exposed surface, and conformational changes are required for
substrate to access the active site (Supplementary Figure 3c). An
open conformation of the active site explains the ability of iPLA2β
to efﬁciently hydrolyze monomeric substrates13 and the lack of a
strong interfacial activation such as observed with cPLA2, where
membrane binding increases activity by several orders of
magnitude63.
The dimer is formed by CAT domains tightly interacting
through an extensive interface, while ANK domains are oriented
outwards from the catalytic core. The existence of the dimer in
solution was conﬁrmed by quantitative sedimentation velocity
and cross-linking experiments. This conﬁguration was veriﬁed by
mutagenesis of the observed dimerization interface and a lack of
oligomerization by isolated ANK domains. The elongated shape
of the dimer contributes to an overestimation of the previously
reported oligomeric state in gel ﬁltration analysis due to faster
migration of elongated molecules through the size-exclusion
matrix. A remote iPLA2β homolog from Caenorhabditis elegans
also forms a dimer in solution22.
The catalytic centers are in immediate proximity to the
dimerization interface and the activity is likely to depend on the
conformation of the dimer. Disruption of the dimer by the
W695E mutation yields an inactive enzyme. The active sites are
also in close proximity to each other and allosterically connected.
Concerted activation of closely integrated active sites should
promote rapid responses upon stimulation by ligands, rendering
the enzyme an efﬁcient sensor of external perturbations.
The close proximity of the active sites provides a plausible
explanation of the previously reported activation mechanism
through autoacylation of Cys651. The reaction occurs in the
presence of oleoyl-CoA and the modiﬁed enzyme is active even in
the presence of CaM/Ca2+60. Cys651 is located at the entrance to
the active site at the base of the membrane-binding loop as well as
at the dimerization interface (Fig. 3d). Covalent attachment of a
long fatty acid chain at this position should increase protein
afﬁnity to the membrane and can alter the conformation of a
CaM-bound dimer. The close proximity of two active sites pro-
vides an explanation for this autoacylation phenomenon impor-
tant for iPLA2β activation in the heart during ischemia.
An intimate allosteric connection of active sites and the
dimerization interface also provides a conceivable mechanism for
inhibition by CaM. Indeed, solution studies and location of the
putative CaM-binding site strongly suggest that a single CaM
binds two molecules of the dimer. We hypothesize that such
interactions will lead to conformational changes in the dimer-
ization interface and alter the conformation of both active sites.
A hypothetical model of two potential states of iPLA2β with
CaM-bound inactive and CaM-free active dimers is illustrated in
Fig. 5. In both states, the enzyme is a dimer. The conformation of












Fig. 5 The proposed mechanism of iPLA2β regulation and macromolecular
interactions. a Schematic representation of the iPLA2β dimer in a
hypothetical inhibited state bound to CaM. CAT domains are shown in blue
and yellow, ANK domains in navy and orange, and a single CaM molecule is
represented by two connected circles in pink. Active site cavities are
represented by narrow channels (gray lines) leading from the solvent-
exposed surface to the Ser/Asp catalytic dyad depicted by magenta. b An
active conformation of the dimer. CaM dissociation leads to the opening of
the active sites. ANK domains are available for interactions with protein
partners as illustrated for CAMKIIβ (light cyan transparent sphere), known
to interact with ANK domain, and with transmembrane Cnx (shown as
transmembrane helix with the C-terminal cytosolic peptide in pale yellow),
which could recruit iPLA2β to the membrane. The Cnx-binding site of
iPLA2β is not known and the hypothetical interaction with ANK domain is
based on similar interaction of AnkB and sodium channel peptide. ATP
binding (red) in the middle of the ANK domain could trigger additional
conformational changes of the AR. Acylation of C651 by oleoyl-coA (green)
can facilitate interaction with the membrane and/or opening of active site
channels. Other conformational states are feasible as well, such as CaM-
bound inhibited protein at the membrane or an open conformation of active
sites in CaM-free form in cytosol, corresponding to the crystallized form
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interaction of CaM with the 1-9-14 motif. Allosterically, CaM
binding stabilizes a closed conformation of the active sites, which
remain open in the absence of CaM. The positions of ATP and of
acyl modiﬁcation are shown in the active form. However, the
exact mechanism of activation through autoacylation and the
effect of ATP binding on protein activity remain to be further
investigated. ANK domains are likely to move out of the con-
formation observed in crystal structure upon approaching the
membrane. In crystals the dimer is shaped as an arch standing on
legs formed by the ANK domains (Fig. 2b), with the CAT
domains at the top and with their active sites facing downward.
The inner radius of the arch is ~80–100 Å. Therefore, in this
conformation the ANK domains can prevent the membrane
surfaces of larger radii from accessing the catalytic domains.
However, the non-speciﬁc hydrophobic interactions permit
rotational ﬂexibility of interacting domains. Therefore, ANK
domains can rotate out of this inhibitory position, while main-
taining hydrophobic contacts with the CAT domain. In fact, the
relative orientation of the ANK and CAT domains is slightly
different between the two monomers of the same crystal. Upon
superposition of CAT domains of two monomers, the resulting
orientation of ANK domains differs with N-terminal ends shifted
by ~12 Å (Supplementary Figure 4c). Similar variation of the
ANK domain orientation is a major source of non-isomorphism
between different crystals.
The model also illustrates a hypothetical interaction of ANK
domains with cytosolic CAMKIIβ and with cytosolic C-terminus
of transmembrane Cnx. The iPLA2β ﬁeld currently lacks a
coherent explanation of how the protein localizes to the mem-
brane of various organelles in different cell types and tissues.
Elongated ARs form highly speciﬁc docking surfaces for different
protein partners and 4–8 ARs are capable of binding several
proteins. The ﬁnding that the ANK domains are oriented towards
the membrane-facing side of iPLA2β suggests that ARs represent
the most logical site of putative interaction with membrane
proteins. Indeed, speciﬁc protein recognition is the only known
function of ARs. The canonical ARs tether cytoskeletal proteins to
ion channels53.
CAMKIIβ has been reported to interact with the N-terminal
part of iPLA2β. The function of such an interaction remains
poorly understood. It can either modulate the activity of either
protein or mediate recruitment of iPLA2β to the membrane since
CaMKIIβ forms complexes with actin, an L-type Ca2+ channel
regulatory protein a1C, and synaptic proteins like NMDA
receptors, densin-180 (a trans-synaptic protein), and α-actinin
(an actin-binding protein). In the case of strong interaction,
CaMKIIβ may also play a role of iPLA2β storage pool due to the
high abundance of CaMKIIβ in neurons (2% of total protein in
hippocampus).
The Cnx-binding domain of iPLA2β remains unknown. This
interaction is particularly interesting in light of growing number
of data implicating iPLA2β function in ER stress response in β-
cells and neurons. Cnx is an ER chaperone protein. It consists of
the luminal domain, single transmembrane helix, and a 90
amino-acid-long C-terminal cytosolic tail, which may potentially
interact with iPLA2β. Interestingly, the interaction of elongated
unstructured peptides was previously reported for the AnkB
protein with both an autoinhibitory peptide and a peptide of the
Nav1.2 voltage-gated sodium channel64. Hypothetically, the ANK
domain of iPLA2β could similarly interact with a portion of Cnx
C-terminal peptide.
The proline-rich 54-residue insert in the long variant is pre-
dicted to form an unstructured loop protruding away from AR9,
which can also interact with other proteins. Alternatively, it can
disrupt the conformation of AR9 and alter orientation of the ANK
domain. The hydrophobic interface between ANK and CAT
domains and the long ﬂexible linker can allow for signiﬁcant
movement of the ANK domain.
Mutations associated with neurodegeneration are found in all
domains, and therefore can affect the enzymatic activity and its
regulation as well as macromolecular interactions of iPLA2β. In
2006, INAD was linked to mutations in the iPLA2β gene
(PARK14)38, which was later connected to a spectrum of neu-
rodegenerative disorders, correspondingly termed PLAN (recent
summary and references in65). Those include INAD (INAD1/










Fig. 6 Positions of selected INAD and PD mutations. Residues mutated in INAD and PD patients are shown as green and red sticks, respectively, on the
cartoon of the iPLA2β monomer. Position of the second monomer is shown as a pale transparent surface. Active site Ser/Asp residues are shown by
magenta spheres. Mutations previously tested for enzymatic activity are labeled. Numbers correspond to the human long variant (L-iPLA2β) sequence with
corresponding numbers of the short variant structure in parentheses
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brain iron accumulation including Karak syndrome (NBIA2B). A
different set of mutations was linked to a rapidly progressive
young-adult onset dystonia-Parkinsonism 3,5,8,9,66-68. As shown
in Figs. 1a and 6, mutations are spread throughout all domains.
Several tested PARK14 mutants retain full22,69 or partial activity3,
while several tested INAD mutations lead to catalytically inactive
enzyme69. An interesting example of sensitive allosteric regula-
tion is Arg 741 (corresponding number in SH-iPLA2β is 687)
located at the dimerization interface, which is mutated to Trp in
INAD, leading to an inactive enzyme, and to Gln in PD with the
activity retained. While an Arg to Trp mutation can signiﬁcantly
alter the conformation of the dimerization interface important for
catalytic activity, it is unclear what effect a minor Arg to Gln
mutation will have and why it causes a late onset (comparatively
to INAD) disease. Surprisingly, the A341T mutation in the ANK
domain was found to be inactive69. This residue is at the ANK/
CAT interface and can affect the interactions and stability of the
protein. It should be noted that there are very few enzymatic and
biochemical studies of the protein and mutants, mostly limited to
semi-quantitative measurements. The structure will facilitate in-
depth analysis of known mutants and their effect on biochemical
properties. This will lead to a better understanding of protein
function and the mechanism of activity and regulation in
numerous cellular pathways and disease states.
The structure should also facilitate ongoing design of small
molecule modulators of iPLA2β for therapeutic purposes. Com-
bined with the analysis of disease-associated mutations, our
results clearly demonstrate the importance of N-terminal and
ANK domains as well as of peripheral regions of the CAT
domain, such as the dimerization interface, for the catalytic
activity and its regulation. Together with further knowledge of
iPLA2β-binding partners, such allosteric regions can be targets for
small molecule binding to inhibit either enzymatic functions or
signaling in downstream pathways.
Methods
Protein puriﬁcation. The pFastBac vector containing the iPLA2β gene cloned from
CHO cells with a C-terminal 6XHisTag was used for protein expression13. The
CHO iPLA2β protein was expressed in Sf9 cells (Invitrogen) using the Bac-to-Bac
system. Bacmid DNA was transfected into Sf9 cells with Trans-IT transfection
reagent (Mirus Bio). After 4 days, the media were collected as the p0 viral stock.
This stock was ampliﬁed by adding 1 ml of p0 to 100 ml of 2 × 106 cells/ml for 96 h,
creating the p1 viral stock. Twenty-ﬁve milliliters of the ampliﬁed p1 was used to
infect 500 ml shaker ﬂasks of 2 × 106 cells/ml for 60 h. The cell pellet was washed
with cold phosphate-buffered saline (PBS) and suspended in puriﬁcation buffer
(25 mM HEPES, pH 7.5, 20% glycerol, 0.5 M NaCl, 1 mM TCEP) containing 50 μg/
ml each of leupeptin and aprotinin. The cell suspension was frozen in liquid
nitrogen and lysed by thawing and sonication at 50% power, 50% duty cycle four
times for 2 min each. The lysate was cleared by ultracentrifugation at 100,000 x g
for 1 h. Urea of 0.5 M and TCEP of 1 mM were added to the supernatant and
mixed with 5 ml of TALON cobalt resin (Clontech) to bind for 1 h at 4 °C. The
resin was centrifuged at 800 x g for 1 min to remove the ﬂow-through fraction in
batch mode. The resin containing the bound protein was then applied to an empty
column, washed sequentially with puriﬁcation buffer containing 10 mM imidazole
(100 ml), 40 mM imidazole (40 ml), and eluted with 15 ml puriﬁcation buffer
containing 250 mM imidazole. iPLA2β and all mutants were >98% pure as deter-
mined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and Coomassie staining.
The CaM expression plasmid was a gift from M. Shea (University of Iowa).
CaM and its mutants were expressed in E. coli BL21 star cells (Thermo Fisher) and
puriﬁed per their detailed protocol70.
Crystallization. iPLA2β was concentrated to 6–8 mg/ml in 10 mM HEPES, pH 7.5,
500 mM NaCl, 10% glycerol, 5 mM ATP, and 1 mM TCEP. Initial crystallization
trials were conducted in sitting-drop plates with a Phoenix robot (Art Robbins
Instruments) using multiple commercial screens from Hampton Research and
Molecular Dimensions. iPLA2β forms crystals within 24 h in several conditions,
and after extensive optimization, two primary conditions were selected: 0.1 M bis-
tris, pH 5.5, 10% PEG3350, 0.2 M Na/K tartrate, and 0.1 M bis-tris, pH 5.5, 10%
PEG3350, 0.2 M sodium acetate. Crystals in sitting-drop conditions displayed poor
diffraction (5–7 Å), high X-ray sensitivity and quick deterioration of diffraction
power after few days, even while continuing to grow in size. Alternatively, a higher
concentration of protein solution was obtained in the presence of CaM. An
equimolar amount of puriﬁed CaM was mixed with iPLA2β, reduced with 5 mM
dithiothreitol (DTT), and dialyzed in 10 mM HEPES, pH 7.5, 150 mM NaCl, 10%
glycerol, 1 mM CaCl2, and 2 mM ATP was added and the proteins were con-
centrated to 10–12 mg/ml. However, the crystals obtained from iPLA2β in the
presence of CaM were identical to those obtained without CaM and SDS-PAGE
analysis demonstrated the absence of CaM in the crystals.
Growth of suitable protein crystals (diffracting to better than 4 Å resolution)
was enabled by the counter-diffusion method in capillaries, originally using the
Granada Crystallization Box (Hampton Research), and, later, using a modiﬁed
capillary method. In this method, the precipitant solution is layered over a plug of
1% agarose into which a ~7 cm long 1 mm diameter glass capillary tube pre-ﬁlled
with protein solution is inserted and sealed at the opposite end. The precipitant
diffuses through the agarose and gradually mixes with protein throughout the
capillary. Importantly, counter-diffusion crystals grew over 1–2 weeks and retained
diffraction for up to 2 months. Crystals were harvested from drops or capillaries
into a cryoprotectant solution containing 68% mother liquor, 10% PEG3350, 10%
ethylene glycol, 10% glycerol, 2% ethanol, and cryo-cooled in liquid nitrogen. Se-
Met-labeled iPLA2β was produced in Sf9 cells with the same procedure as native
protein, except for using methionine-deﬁcient medium (Expression Systems, Davis,
CA, USA) and supplementing with 100 mg/L L-selenomethionine 16 h after
infection. The I701D mutant, which had 2–3 times greater expression than wild
type, was used for the production of the Se-Met protein. Puriﬁcation and
crystallization of the Se-Met derivative was the same as for native protein.
Structure determination. X-ray diffraction data were collected on GM/CA@APS
beamlines 23-ID-B and 23-ID-D at the Advanced Photon Source, Argonne
National Laboratory. Data collection and reﬁnement statistics are shown in Sup-
plementary Table 1. To identify parts of crystals suitable for data collection, more
than 400 samples were tested with the raster method using a small (5–20 μm)
beam. The best data sets were collected from elongated crystals using the helical
method in order to spread the absorbed dose over larger volume of the crystal and
thus reduce the radiation damage to the samples71. Data were processed and scaled
with HKL200072. It was important to use the “autocorrection” option during
scaling, which resulted in rejection of 14% weak reﬂections due to strong aniso-
tropy of diffraction. Note, that the ﬁnal statistics after rejection with “auto-
correction” was not reported in HKL2000 output. The data were analyzed with
Xtriage program within the Phenix program suite and completeness and aniso-
tropy parameters are shown in Supplementary Table 1. Analysis of all data scaled
without “autocorrection” in STARANISO server (Global Phasing Limited) resulted
in similar number of rejections and anisotropic diffraction limits. Overall, the
anisotropy correction reduced the data set completeness, while yielding strong data
at resolution higher than 4.4 Å along c*-axis (e.g., Iσ(I) is 4.5 in highest resolution
shell (3.95–4.0 Å), instead of 1.6 for all data reported by HKL2000). Scaling with
“autocorrection” also resulted in data with a lower Wilson B factor and, most
importantly, in signiﬁcantly more detailed electron density maps, even compara-
tively to data processed with other anisotropy reduction programs.
Data from the Se-Met protein crystal were collected at the selenium absorption
peak and inﬂection wavelengths using helical mode and inverse beam geometry
with a 30° wedges. Analysis of MAD data at two wavelengths with the Phenix
suite73 did not yield a solution. SAD data using peak wavelength produced a
solution with seven selenium peaks. An MR solution was obtained using two
different protein models, a patatin55 and four ARs of an ankyrin-R protein53. The
structure of patatin was manually trimmed to retain only structural core elements
overlapping with CAT domain residues accordingly to the sequence alignment.
The Sculptor program within Phenix was used to prepare four ARs from PDB
1N11. The MR solution contained two copies of each domain. Combination of
SAD with MR solution resulted in 51 selenium peaks and a high-quality electron
density map (Supplementary Figure 2) sufﬁcient for modeling of ﬁve additional
ARs and several loop regions within the CAT domain. Connectivity of CAT and
ANK domains was veriﬁed by analysis of all pairs of symmetry-related ANK and
CAT domains in the crystal lattice which yielded only one pair with sufﬁciently
short distance. The large number of methionines spread throughout the entire
sequence permitted an unambiguous assignment of amino acids. During
consecutive steps of structural modeling, combined MR/SAD electron density
maps were calculated with one of the domains omitted to avoid model bias. Only
one copy of each domain was modeled and the structure was reﬁned using a global
NCS function and secondary-structure geometry restriction. After completion of
model building, the structure was subsequently reﬁned using 3.95 Å resolution data
from the native protein crystal. Simulated annealing composite omit maps were
extensively used in model building. Several rounds of Rosetta reﬁnement in Phenix
were used for the ﬁnal model. Phi-psi values of 82% of the residues in the ﬁnal
model are in a favorable region of the Ramachandran plot with 0.4% in an
unfavorable conformation. The latter were in loop regions with poor electron
density. Residues 1–80, 95–103, 113–117, 129–145, 405–408, and 652–670 were
omitted from ﬁnal model and regions 81–94, 104–112 (numbering in both regions
is based on secondary-structure prediction), and 409–416 were modeled as alanine
residues.
The 4.6 Å resolution SAD data were collected at selenium peak wavelengths
from protein crystals soaked with 2′MeSe-ATP (Jena Bioscience). Combined MR/
SAD analysis revealed a single peak. Several alternative models with different
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omitted domains or domain fragments were used to avoid model bias. All
calculations resulted in an identical position of the selenium peak.
Fluorescent phospholipase activity assay. The continuous activity assay was
adapted from a protocol used for sPLA274. Pyrene-PC (Thermo Fisher #H361)
(Supplementary Figure 7a, b) was dissolved as a 1 mM stock in dimethyl sulfoxide.
The solution was injected into a glass vial containing assay buffer (25 mM HEPES
7.5, 150 mM NaCl, 10% glycerol) over 1 min with shaking to create the substrate
mixture. This method resulted in liposomes averaging 100 nm in diameter as
determined by dynamic light scattering. One hundred microliters of substrate
mixture was added to a black 96-well microplate with a non-binding surface
(Corning #3650). Fatty acid-free BSA of 0.2% in the buffer acted as an acceptor for
the hydrolyzed 1-pyrenedecanoic acid. Proteins were dialyzed against the assay
buffer. iPLA2β was incubated with different concentrations of CaM with or without
1 mM CaCl2 for 15 min. The baseline ﬂuorescence of the substrate was recorded for
3 min at 340 nm excitation/400 nm emission using the monochromator of a Biotek
Synergy 4 plate reader. Ten microliters of the protein mixture was added to initiate
reaction. After a 5 s mixing step, the ﬂuorescence was read every 30 s for 1 h or
until the signal reached a plateau (Supplementary Figure 7c). The linear slope of
the ﬁrst 5 min of the reaction was used as the initial velocity. The CaM inhibition
data were ﬁt to the Hill equation using Origin 8.6 software. The velocity in
ﬂuorescence units per time was quantiﬁed in moles using a standard curve of the 1-
pyrenedecanoic acid product.
Fluorescence anisotropy-binding assays. As CaM has no native cysteine resi-
dues, a mutant was engineered at Thr34, as described previously75, to enable
coupling of FAM ﬂuorophore in a site-directed manner. This enabled to measure
direct binding of FAM-CaM the using ﬂuorescence anisotropy method. The CaM
T34C mutant was created by mutagenesis, conﬁrmed by sequencing, and puriﬁed
with the same procedure as described for the native protein. The labeled protein
was separated from excess FAM with phenyl sepharose in the same procedure as
for puriﬁcation. The concentration of labeled protein was measured at 495 nm with
a molar extinction coefﬁcient of 68,000/M/cm. For the ﬂuorescence-binding assay,
proteins were dialyzed to the assay buffer (25 mM HEPES 7.5, 150 mM NaCl, 10%
glycerol). CaM-FAM (30 nM ﬁnal concentration) was incubated with a series of
iPLA2β concentrations obtained by twofold serial dilution in a 384-well non-
binding plate (Corning #3573) in a total volume of 80 μL. After 15 min incubation
at 25 °C, the overall ﬂuorescence intensity and the parallel and perpendicular
components were read on a Biotek Synergy 4 with 485 nm excitation and 528 nm
emission ﬁlters. The ﬂuorescence anisotropy was calculated by the Biotek
Gen5 software using the following equation: A ¼ ðFjj  F?Þ=ðFjj þ 2F?Þ, where Fjj
and F? are the parallel and perpendicular intensities, respectively. Each experiment
was conducted in triplicate at least two independent times and values shown are
the average ± s.e.m.
Analytical ultracentrifugation. Proteins were extensively dialyzed against AUC
buffer (25 mM HEPES 7.5, 500 mM NaCl, 10% glycerol). Sedimentation velocity
studies were performed in a Beckman XL-A analytical ultracentrifuge at 20 °C and
35,000 rpm. The absorbance at 280 nm was collected every 4 min for a total of
200 scans. The buffer viscosity and density as calculated by Sednterp (http://www.
rasmb.org/sednterp) were 1.04913ρ and 0.01436η, respectively. These values were
used to ﬁt the data to the Lamm equation in SEDFIT software76 using the con-
tinuous c(s) distribution model. Graphs were prepared using GUSSI software (UT
Southwestern).
Data availability. Atomic coordinates and structure factors for the iPLA2β
structure have been deposited in the Protein Data Bank under accession code
PDBID 6AUN. All reagents and relevant data are available from the authors upon
request.
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